ECE2010 Poster Presentations Neuroendocrinology and Pituitary (<emphasis role="italic">Generously supported by Novartis</emphasis>) (125 abstracts)
1Department of Physiology, Pamukkale University, Denizli, Turkey; 2Department of Endocrinology, Pamukkale University, Denizli, Turkey.
Background: Acromegaly is associated with increased morbidity and mortality from cardiovascular disease. Hypertension is a number of common cardiovascular risk factors in acromegalic patients. The aim of this study was to investigate association between the frequencies of angiotensin converting enzyme (ACE) I/D and angiotensinogen (AGT) M235T polymorphisms, the genes belongs to the reninangiotensinaldosterone system, and clinical parameters of acromegaly patients.
Methods: Total of 33 acromegalic patients and 63 controls were enrolled ttto study. We determined the ACE I/D and AGT M235T gene polymorphism. Serum insulin, glucose, triglyceride, HDL-cholesterol, LDL-cholesterol, GH and IGF1 levels of subjects were analyzed.
Results: Distribution of I/D polymorphism of the ACE in acromegaly patients and controls were as follows: 57.6% DD, 33.3% ID, 9.1% II genotype, whereas in control group, 50.8% DD, 42.9% ID, 6.3% II genotype. AGT M235T genotypes distributed in patients and controls were as follows: 12.1% MM, 63.6% MT, 24.2% TT patients and 19%MM, 60.3% MT, 20.6% TT healthy subjects. The frequency of genotype ACE and M235T AGT gene was not significantly different between control and patients. In acromegaly patients, clinical characteristics among the three ACE genotype, DD, ID and II, did not display any significant difference. A significant difference in the serum systolic blood pressure and IGF-I levels among the three AGT genotype, MM, MT and TT genotypes was found in patient group. In MT genotypes individuals systolic blood pressure and IGF-I levels was found significantly higher than MM and TT genotypes with subjects, P<0.05. In addition, triglyceride and HDL levels between MM and MT genotypes differed significantly, P<0.05.
Conclusions: It can be say that angiotensinojen gene genotypes carriers may have more risk than other genotypes individuals for development hypertension in acromegaly.